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e appreciate the comments from Drs. Kassimatis and Konstanti-
opoulos concerning our review (1). The pre-clinical evidence
uggesting that statins may cause renal fibrosis, mediated by
ransforming growth factor-beta signaling, is interesting but does
ot negate other pre-clinical studies suggesting reno-protection.
hen examining the randomized controlled clinical trial evidence
the gold standard), the totality of evidence does not indicate a
tatin-induced deleterious effect (2,3). A detailed discussion of
re-clinical trials was beyond the scope of our review, and it was
ur goal to provide some balance and perspective to the inordinate
mount of attention focused on statin-induced proteinuria after
he introduction of rosuvastatin.
We acknowledge that some pre-clinical trials indicate statins
ay have an immunomodulatory role; however, prospective ran-
omized controlled trials to date do not demonstrate a clinically
ignificant effect. In the 4D (Die Deutsche Diabetes Dialyse
tudie) trial with diabetic hemodialysis patients, there was no
ignificant difference in fatal infections in the atorvastatin arm
n 60) compared with that in the placebo arm (n 68) (4). The
LERT (Assessment of Lescol in Renal Transplantation Trial)
tudy was comprised of renal transplant patients with varying
egrees of renal insufficiency who were immunocompromised due
o cyclosporine and other immunosuppressant drugs, yet fluva-
tatin and placebo infection rates were not significantly different
fluvastatin [n  25], placebo [n  26]) (5).
Finally, we do not advocate the use of statins as renoprotective
gents; however, we do not believe there is sufficient evidence to
iscourage the use of these agents in chronic kidney disease (CKD)
atients who are at high risk of developing coronary heart disease
1). In fact, the National Kidney Foundation clinical practice
uidelines state that CKD patients should be placed in the “highest
isk” category for cardiovascular disease (6). The real question is
ot whether statins are a double-edged sword; rather, are they an
nderutilized weapon in the battle to prevent coronary heart
isease in CKD patients?
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he DELFT (Drug Eluting
tent for LeFT main) Registry:
he Unknowns
eliga et al. (1) are to be congratulated on their report from the
ELFT (Drug Eluting stent for LeFT main) registry of “long-
erm” outcomes after drug-eluting stents for unprotected left main
oronary artery disease.
They raise, however, 3 important issues that need further
larification.
First, rather than presenting total mortality, which is obligatory
or reporting of surgical outcomes, they present the incidence of
ardiac death, according to the Academic Research Consortium
efinition. This sets a dangerous precedent, as cardiac mortality is
less objective outcome measure than total mortality, and a better
ompromise would be to present both; presentation of total
ortality should, however, remain mandatory.
Second, during the period of the study, 680 patients underwent
oronary artery bypass grafting in the 7 participating centers.
here are no data to inform whether coronary artery bypass
rafting patients differed systematically from those undergoing
tenting in terms of complexity of left main disease, severity of
oncomitant multivessel coronary artery disease, existence of co-
orbid conditions, or, indeed, how the decision was made as to
hich intervention patients would receive.
Third, there is no explicit statement as to whether all interven-
ions were decided by a multidisciplinary team including a surgeon.
he increasing tendency to report interventional treatments being
ased on “patient or physician preference” is both inadequate and
nappropriate because it reduces the likelihood that patients will
eceive impartial information and, as a consequence, will not
nsure that there is, therefore, real patient choice and genuine
nformed consent. Unless a patient is clearly unfit or unwilling to
ursue a surgical option, discussion of all interventions by a
ultidisciplinary team should be a minimum standard of care
2–4).
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e would like to thank Dr. Taggart for his interest in our study
1) and his thoughtful comments. We would like to address each
oint separately.
Dr. Taggart states that: “Rather than presenting total mortality,
hich is obligatory for reporting of surgical outcomes, they present
he incidence of cardiac death, according to the Academic
esearch Consortium definition. This sets a dangerous precedent,
s cardiac mortality is a less objective outcome measure than total
ortality, and a better compromise would be to present both;
resentation of total mortality should, however, remain mandatory.”
The main aim of the DELFT registry (1) was to assess
ong-term clinical outcome among patients undergoing percuta-
eous coronary intervention for unprotected left main coronary
rtery disease. Cardiac death is reported because we think this
arameter reflects the direct effect of the interventional treatment
n patients’ prognosis. Cardiac death is reported in concordance
ith the Academic Research Consortium definition and is specific
or and directly related to the treatment under investigation (2).
ccording to the Academic Research Consortium definition, “all
eaths are considered cardiac unless an unequivocal non-cardiac
ause can be established.” Moreover, “any unexpected death even
n patients with coexisting potentially fatal non-cardiac disease
e.g., cancer, infection) is classified as cardiac.” For this reason, we
hink that cardiac mortality should not be considered less objective
ut rather a more specific outcome measure. However, we do
ccept that concurrent reporting of total mortality adds additional
nformation. In the DELFT registry (n  358), the incidence of
otal death at 1 and 3 years was 7% (25 patients vs. 24 cardiac
eaths) and 11.2% (40 patients vs. 33 cardiac deaths), respectively.
n elective patients (n 288), total death at 1 and 3 years was 3.8%
11 patients vs. 11 cardiac deaths) and 8.3% (24 patients vs. 18 cardiac
eaths). These results are in line with previous reports (3–5).
The second point made by Dr. Taggart is: “During the period
f the study, 680 patients underwent coronary artery bypass
rafting in the 7 participating centers. There are no data to inform
hether coronary artery bypass grafting patients differed system-
tically from those undergoing stenting in terms of complexity of
eft main disease, severity of concomitant multivessel coronary
rtery disease, existence of comorbid conditions, or, indeed, how
he decision was made as to which intervention patients would
eceive.”
We would like to point out that we reported the number of
oronary artery bypass grafting (CABG) procedures performed
oncomitantly to give to the reader an idea of the surgical
rocedural volume in the participating centers over the same time
eriod. It is beyond the scope of the DELFT registry to provide a
omparison between CABG and percutaneous coronary interven-
ion, and, therefore, demographic data relevant to CABG cases
ere not provided. We do intend to address this question with
ubsequent analyses.The third point made by Dr. Taggart is that “there is no explicit
tatement as to whether all interventions were decided by a
ultidisciplinary team including a surgeon. The increasing ten-
ency to report interventional treatments being based on ‘patient
r physician preference’ is both inadequate and inappropriate
ecause it reduces the likelihood that patients will receive impartial
nformation and, as a consequence, will not ensure that there is,
herefore, real patient choice and genuine informed consent.
nless a patient is clearly unfit or unwilling to pursue a surgical
ption, discussion of all interventions by a multidisciplinary team
hould be a minimum standard of care.”
In response, we would like to note that, as previously described
y our group (6), the current standard of care for patients with
ignificant unprotected left main coronary artery disease is to have
hem evaluated by both an interventional cardiologist and cardiac
urgeon and to reach consensus regarding optimal management. In
aking this decision, the hemodynamic conditions, lesion, and
essel characteristics; presence of comorbidities; quality of arterial
nd/or venous conduits for grafting; and patient and/or referring
hysician preference should be considered. This can be done at a
ultidisciplinary conference or by direct consultation in the acute
etting and is standard practice at the contributing institutions in
ur registry.
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